By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
LATEST POSTS
- 1
Find the Standards of Powerful Cooperation: Accomplishing Cooperative energy and Coordinated effort - 25 High Limit Outer Hard Drives For Information Stockpiling
- 3Current Chateaus: Advancement and Style
- 4China resumes flights to North Korea after a six-year pause
- 5Vote in favor of the wide open action that revives your brain and soul!
- Rachael Ray is navigating grief this holiday season. She doesn't have time for 'negative energy' on the internet.
- Is new Harry Styles music on the way? Fans think so, after a cryptic website and posters pop up.
- First part of major new German-Danish tunnel cleared for lowering
- 'You're no longer my sister' - rows erupt as war divides Iranian families
- Four countries to boycott Eurovision 2026 over Israel’s inclusion
- How we came to be: Scientists get first look at the evolution of early complex animals
- Flu activity rises sharply across US with 7.5 million cases, CDC data shows
- Pulsars to the extreme: Spinning dead stars found blasting radio signals from the 'edge of their magnetic reach'
- Everything to know about NASA's moon mission launching this week
